Glibenclamide And Metformin Oral Tablets (immediate-release) Generics - Manufacturers & Suppliers
Glucovance®,®, Euglucon-M®, Glyburid-M®(EU & US)
| Product/Composition:- | Glibenclamide and Metformin Oral Tablets (Immediate-Release) |
|---|---|
| Strength:- | Glibenclamide 2.5 mg + Metformin 500 mg; Glibenclamide 5 mg + Metformin 500 mg |
| Form:- | Tablets IR |
| Reference Brands:- | Glucovance®,®, Euglucon-M®, Glyburid-M®(EU & US) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
This dual formulation combines Glibenclamide, a sulfonylurea that stimulates insulin secretion, and Metformin, which reduces hepatic glucose production and improves insulin sensitivity. The synergistic effect offers better glycemic control in type 2 diabetes, reducing fasting and postprandial glucose levels. It lowers HbA1c effectively and is suitable when monotherapy fails.
Glibenclamide (Glyburide) + Metformin tablets are approved in several EU countries under fixed-dose combinations and were previously marketed in the USA as Glucovance®. However, due to evolving safety guidelines—especially related to hypoglycemia risk—its availability may vary. In the EU, these combinations are still prescribed under close monitoring for type 2 diabetes management. The European Medicines Agency (EMA) requires risk-benefit evaluation and labeling for renal monitoring. The U.S. FDA formerly approved Glucovance® under NDA 021178. Healthcare buyers and distributors can find these formulations via Pharmatradz.com for compliant global sourcing.